Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IBA/ABC

Executive Summary

BIO (Biotechnology Industry Organization) is probable name for new trade group to be formed from merger of the Industrial Biotechnology Association and the Association of Biotechnology Companies ("The Pink Sheet" Oct. 12, T&G-1). Final details of the merger are being negotiated by ABC Chairman Tom Wiggans (CytoTherapeutics) and IBA Chairman Stephen Duzan (Immunex). Richard Godown and William Small, current executives of IBA and ABC, are expected to head sections of BIO to serve companies that now comprise membership of their respective associations. The first group of candidates being interviewed for chief executive of BIO include Glaxo lobbyist Geoffrey Littlehale, formerly an aide to Rep. Synar (D-Okla.) and Capitol Hill contact for the Pharmaceutical Manufacturers Association, and Patent & Trademark Office Acting Commissioner Douglas Comer, formerly a subcommittee aide to Sen. Dole (R-Kan.) and legislative counsel with the Washington law office of Akin Gump Strauss.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS021804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel